Compare Cronos Group Inc (CRON) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Kimberly Clark Corp — how do they compare? Cronos Group Inc trades at $3.11 (market cap $1.14B), while Kimberly Clark Corp trades at $108.93 (market cap $36.11B). The key difference: Kimberly Clark Corp is far larger — about 31.7× Cronos Group Inc's market cap, and Kimberly Clark Corp pays a 4.72% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | KMB | |
|---|---|---|
Market Cap | $1.14B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $3.27 | $134.81 |
52-Week Low | $2.30 | $93.05 |
Enterprise Value | $341.13M | $41.67B |
Dividend Yield | — | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.00, down 3.23% today, with a bullish technical signal from moving averages. The company showed strong Q2 2026 performance with 58% YoY revenue growth and earnings beat, though recent quarters were mixed. Valuation metrics include P/E of 16.21 and P/S of 6.55, while profitability improved with 45.86% gross margin. Analyst consensus is mixed with 20% buy, 60% hold ratings.
Outlook remains positive due to international expansion and strong product positioning, particularly in Canada and Europe. Key risks include competitive pressures and cash flow volatility from aggressive investing. The stock presents growth potential but requires monitoring of execution and market conditions.
Kimberly-Clark (KMB) trades at $108.02, down 1.51% today, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings missed expectations, prompting a lowered 2026 outlook due to China diaper market weakness and North American volatility. The company maintains strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, but faces revenue pressure with 2025 sales at $16.45B, down from prior years. Dividend payments remain steady at $1.28 per share, supporting income investors.
KMB presents a cautious outlook with near-term headwinds overshadowing long-term strengths. Investment opportunities include a discounted valuation relative to historical levels and a reliable dividend yield. Key risks involve execution challenges in China, competitive pressures, and macroeconomic sensitivity. Analyst consensus is mixed, with a $113.20 price target suggesting modest upside, but investors should weigh operational uncertainties against the company's brand resilience and cost-saving initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
